MedTrace Logo

Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Japanese Patients With Essential Hypertension

NCT01599104 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1161

Last updated 2015-10-16

Study results available
· View outcomes & findings →

Summary

This study assessed the efficacy of LCZ696 in Japanese patients with essential hypertension

Conditions

  • Essential Hypertension

Interventions

DRUG

LCZ696

200 mg (one tablet) or 400 mg (2 tablets of 200mg) once daily

DRUG

Olmesartan

Olmesartan 20 mg capsule one daily

DRUG

Placebo

Placebo to LCZ696 or Olmesartan

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-30
Primary Completion
2013-04-30
Completion
2013-04-30

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01599104 on ClinicalTrials.gov